Auction process initiated for ST-503 program for chronic neuropathic pain, expected to be completed in fourth quarter of 2026 Previously announced asset sale transactions with PTC and Lilly have closed, generating 163.55
Why Is Sangamo Therapeutics, Inc. (SGMO) Stock Up Today?
Updated Nov 16, 2026 2:36 PM ET · Prev Close $0.14
Session Regime & Catalyst Assessment
68% Signal ConvictionSangamo Therapeutics, Inc. Advancing 31.56% on 6.50x Relative Volume
Sangamo Therapeutics, Inc. (SGMO) is advancing 31.56% (+$0.04) to $0.18 on 6.50x average session volume. Relative to benchmarks, SGMO is outperforming the S&P 500 by +33.45%. 14-day RSI stands at 38.4, keeping momentum in a bearish regime.
Auction process initiated for ST-503 program for chronic neuropathic pain, expected to be completed in fourth quarter of 2026 Previously announced asset sale transactions with PTC and Lilly have closed, generating 163.55
Price ($0.18) trades relative to 20-day SMA ($0.23) and 50-day SMA ($0.31).
Market & Sector Relative Strength
SGMO outperforming the S&P 500 by +33.45%Options Flow & Execution Desk
Recent SGMO Catalyst Headlines
Verified WireWall Street analysts view the deal as a risky, high-reward bet on a treatment that s nearing a possible regulatory approval and could be superior to existing medications.
PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec Lilly to purchase capsid delivery, zinc finger and modular integrase MINT platforms and prion disease program Proposed sales subject to final
Key players include Beam Therapeutics, Twist Bioscience, Sangamo, Editas Medicine and Tessera Therapeutics. Profiles cover gene-writing technologies, products, applications, trends and competition.Dublin, Oct. 29, 2026 G
1–3 Day Expected Range & Key Level
54% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $0.22 (session resistance) for directional breakout confirmation.
Technical Regime (SGMO)
BEARISH MA TRENDRetail & Crowd Sentiment
BullishBullish sentiment dominates $SGMO on StockTwits with traders expressing optimism about the stock's performance and potential partnerships with companies like Palantir Technologies ($PLTR). No recent news articles were available.
About Sangamo Therapeutics, Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, Als/Ftd, and Huntington's Disease; and …
Get Instant SGMO Catalyst Alerts
Receive an email alert when SGMO triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversSGMO Session & Catalyst FAQ
Why is SGMO stock up today?
Sangamo Therapeutics, Inc. (SGMO) is advancing 31.56% (+$0.04) to $0.18 on 6.50x average session volume. Relative to benchmarks, SGMO is outperforming the S&P 500 by +33.45%. 14-day RSI stands at 38.4, keeping momentum in a bearish regime.
Is SGMO stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 6.50x relative volume (high participation). Our multi-factor model currently rates SGMO as HOLD. Review full valuation, quality, and timing signals on the SGMO Buy or Sell Decision Brief →
What is SGMO's intrinsic value and expected trading range?
At $0.18, SGMO's modeled 1-to-3 session range is $0.17 – $0.19, with a key inflection level at $0.22 (session resistance). Compare current price against multi-year cash flow projections in the SGMO Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for SGMO?
RSI at 38.4 reflects soft below-midline momentum. SGMO trades at $0.18 relative to its 20-day SMA ($0.23) and 50-day SMA ($0.31), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.